No registrations found.
ID
Source
Brief title
Intervention
Outcome measures
Primary outcome
Poor outcome (dependence or death) 3 months after the subarachnoid hemorrhage (Rankin 0-3 versus Rankin 4-5, or death) as assessed with the modified Rankin scale during a telephone interview. Dependence will be defined as a Rankin score > 3.
Secondary outcome
No symptoms 3 months after the subarachnoid hemorrhage (Rankin 0 versus Rankin 1-5 or death).
Global change in Rankin score.
Background summary
The MASH study is a prospective randomized, placebo-controlled, international multicenter trial to determine whether magnesium reduces the frequency of poor outcome (death or dependence) in patients admitted within 4 days after aneurysmal subarachnoid hemorrhage.
Study objective
N/A
Intervention
Magnesium sulfate 64 mmol/d (or placebo) is started intravenously as soon as possible after informed consent and continued until 20 days after the hemorrhage.
P.O. Box 85500
Walter M. Bergh, van den
Utrecht 3508 GA
The Netherlands
+31 (0)30 2508350
w.m.vandenbergh@neuro.azu.nl
P.O. Box 85500
Walter M. Bergh, van den
Utrecht 3508 GA
The Netherlands
+31 (0)30 2508350
w.m.vandenbergh@neuro.azu.nl
Inclusion criteria
Aneurysmal subarachnoid hemorrhage.
Exclusion criteria
1. Renal failure (creatinin > 150),
2. age < 18 jaar,
3. weight < 50 kg,
4. no informed consent,
5. death is imminent.
Design
Recruitment
Followed up by the following (possibly more current) registration
No registrations found.
Other (possibly less up-to-date) registrations in this register
No registrations found.
In other registers
| Register | ID |
|---|---|
| NTR-new | NL29 |
| NTR-old | NTR50 |
| Other | : N/A |
| ISRCTN | ISRCTN68742385 |